Aptevo Therapeutics Inc.
APVO
Price:
$0.3362
Market Cap:
$3.17M
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO44...[Read more]
Industry
Biotechnology
IPO Date
2016-07-20
Stock Exchange
NASDAQ
Ticker
APVO
The ROE as of September 2024 (TTM) for Aptevo Therapeutics Inc. (APVO) is -266.14%
According to Aptevo Therapeutics Inc.’s latest financial reports and current stock price. The company's current ROE is -266.14%. This represents a change of 217.65% compared to the average of -83.78% of the last 4 quarters.
Aptevo Therapeutics Inc. (APVO) Historical ROE (quarterly & annually)
How has APVO ROE performed in the past?
The mean historical ROE of Aptevo Therapeutics Inc. over the last ten years is -311.53%. The current -266.14% ROE has changed -14.57% with respect to the historical average. Over the past ten years (40 quarters), APVO's ROE was at its highest in in the March 2022 quarter at 169.29%. The ROE was at its lowest in in the December 2021 quarter at -515.79%.
Average
-311.53%
Median
-126.82%
Minimum
-2246.13%
Maximum
237.39%
Aptevo Therapeutics Inc. (APVO) ROE by Quarter and Year
Discovering the peaks and valleys of Aptevo Therapeutics Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.92%
Maximum Annual ROE = 237.39%
Minimum Annual Increase = -Infinity%
Minimum Annual ROE = -2246.13%
| Year | ROE | Change |
|---|---|---|
| 2023 | -142.47% | -160.01% |
| 2022 | 237.39% | -110.57% |
| 2021 | -2246.13% | 1.92% |
| 2020 | -111.17% | -67.45% |
| 2019 | -341.56% | 93.44% |
| 2018 | -176.57% | -2177.33% |
| 2017 | 8.50% | -103.82% |
| 2016 | -222.31% | 232.13% |
| 2015 | -66.94% | 23.89% |
| 2014 | -54.03% | -Infinity% |
Aptevo Therapeutics Inc. (APVO) Average ROE
How has APVO ROE performed in the past?
The current ROE of Aptevo Therapeutics Inc. (APVO) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-717.07%
5-year avg
-520.79%
10-year avg
-311.53%
Aptevo Therapeutics Inc. (APVO) ROE vs. Peers
How is APVO’s ROE compared to its peers?
Aptevo Therapeutics Inc.’s ROE is greater than Kronos Bio, Inc. (-68.82%), less than Cyclerion Therapeutics, Inc. (28.07%), greater than Larimar Therapeutics, Inc. (-37.84%), greater than Addex Therapeutics Ltd (-456.73%), greater than Achilles Therapeutics plc (-47.36%), less than Nutriband Inc. (0%), greater than Quoin Pharmaceuticals, Ltd. (-76.31%), greater than Longeveron Inc. (-112.11%), greater than RenovoRx, Inc. (-246.98%), greater than Virax Biolabs Group Limited (-403.38%), greater than Passage Bio, Inc. (-115.10%), greater than Magenta Therapeutics, Inc. (-70.73%), greater than TRACON Pharmaceuticals, Inc. (-61.71%), greater than Invivyd, Inc. (-237.65%), greater than Avenue Therapeutics, Inc. (-109.72%), greater than Hoth Therapeutics, Inc. (-749.10%), greater than Revelation Biosciences, Inc. (-81.79%), greater than NeuroBo Pharmaceuticals, Inc. (-243.91%), greater than null (-154.04%),
| Company | ROE | Market cap |
|---|---|---|
| -68.82% | $56.02M | |
| 28.07% | $7.86M | |
| -37.84% | $431.33M | |
| -456.73% | $15.93M | |
| -47.36% | $28.99M | |
| 0% | $50.03M | |
| -76.31% | $2.45M | |
| -112.11% | $29.65M | |
| -246.98% | $26.15M | |
| -403.38% | $12.42M | |
| -115.10% | $46.32M | |
| -70.73% | $42.44M | |
| -61.71% | $204.45K | |
| -237.65% | $137.96M | |
| -109.72% | $4.00M | |
| -749.10% | $6.89M | |
| -81.79% | $1.50M | |
| -243.91% | $30.52M | |
| -154.04% | $0 |
Build a custom stock screener for Aptevo Therapeutics Inc. (APVO) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Aptevo Therapeutics Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Aptevo Therapeutics Inc. (APVO) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Aptevo Therapeutics Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Aptevo Therapeutics Inc.'s ROE?
How is the ROE calculated for Aptevo Therapeutics Inc. (APVO)?
What is the highest ROE for Aptevo Therapeutics Inc. (APVO)?
What is the 3-year average ROE for Aptevo Therapeutics Inc. (APVO)?
What is the 5-year average ROE for Aptevo Therapeutics Inc. (APVO)?
How does the current ROE for Aptevo Therapeutics Inc. (APVO) compare to its historical average?